虽然现在乳腺癌的治疗有了显著的进步,然而转移性,尤其是三阴性乳腺癌(TNBC),低生存率仍然具有挑战性。癌症免疫疗法,HER2阳性和TNBC的一种有希望的方法,仍然面临阻力障碍。最近,许多研究都将目光投向了乳腺癌免疫治疗的耐药性。我们的研究提供了对当前研究环境的透彻理解,热点,通过细致的文献计量分析,在这一关键领域取得了新的突破。截至2024年3月26日,共收集了1341篇关于乳腺癌免疫学抗性的文章,来自WebofScienceCoreCollection。包括765篇文章和576条评论。Bibliometrix,CiteSpace和VOSviewer软件每年用于检查出版物和引文,多产的国家,有贡献的机构,高水平的期刊和学者,以及被高度引用的文章,引用和关键字。在过去的七年中,乳腺癌免疫治疗耐药性的研究出现了惊人的增长。美国和中国作出了重大贡献,哈佛医学院是最多产的机构,并积极参与合作。最有贡献的作者是库里利亚诺,G来自意大利欧洲肿瘤研究所,而Wucherpfennig,K.W.来自美国达纳-法伯癌症研究所,引用次数最高。高产期刊主要集中在临床上,免疫学和肿瘤学研究。常用关键词包括\"阻力\",\"表达式\",“肿瘤微环境”,\"癌症\",\"T细胞\",“治疗”,“化疗”和“细胞”。目前的研究试图通过整合生物信息学来揭示乳腺癌的免疫抵抗机制,基础实验,和临床试验。正在努力制定提高免疫疗法有效性的策略,包括联合疗法的探索和药物输送系统的进步。此外,人们非常关注鉴定能够预测患者对免疫学反应的新型生物标志物.这项研究将为研究人员提供有关乳腺癌免疫学耐药性的现有知识的最新概述,作为明智决策和进一步研究解决免疫疗法耐药性的创新方法的宝贵资源。
While breast cancer treatments have advanced significantly nowadays, yet metastatic, especially triple-negative breast cancer (TNBC), remains challenging with low survival. Cancer immunotherapy, a promising approach for HER2-positive and TNBC, still faces resistance hurdles. Recently, numerous studies have set their sights on the resistance of immunotherapy for breast cancer. Our study provides a thorough comprehension of the current research landscape, hotspots, and emerging breakthroughs in this critical area through a meticulous bibliometric analysis. As of March 26, 2024, a total of 1341 articles on immunology resistance in breast cancer have been gathered from Web of Science Core Collection, including 765 articles and 576 reviews. Bibliometrix, CiteSpace and VOSviewer software were utilized to examine publications and citations per year, prolific countries, contributive institutions, high-level journals and scholars, as well as highly cited articles, references and keywords. The research of immunotherapy resistance in breast cancer has witnessed a remarkable surge over the past seven years. The United States and China have made significant contributions, with Harvard Medical School being the most prolific institution and actively engaging in collaborations. The most contributive author is Curigliano, G from the European Institute of Oncology in Italy, while Wucherpfennig, K. W. from the Dana-Farber Cancer Institute in the USA, had the highest citations. Journals highly productive primarily focus on clinical, immunology and oncology research. Common keywords include \"resistance\", \"expression\", \"tumor microenvironment\", \"cancer\", \"T cell\", \"therapy\", \"chemotherapy\" and \"cell\". Current research endeavors to unravel the mechanisms of immune resistance in breast cancer through the integration of bioinformatics, basic experiments, and clinical trials. Efforts are underway to develop strategies that improve the effectiveness of immunotherapy, including the exploration of combination therapies and advancements in drug delivery systems. Additionally, there is a strong focus on identifying novel biomarkers that can predict patient response to immunology. This study will provide researchers with an up-to-date overview of the present knowledge in drug resistance of immunology for breast cancer, serving as a valuable resource for informed decision-making and further research on innovative approaches to address immunotherapy resistance.